DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) — Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been successfully completed in Colombia, marking a major...
Clinical validation study with PrismTcell use achieved approximately 2-fold higher ACR50 response rate to abatacept. FOR IMMEDIATE RELEASE Durham, NC.–(BUSINESS WIRE)–[Month Day], 2026–Scipher Medicine (Scipher), a leader in immunology precision...
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the...
FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them.” ~ Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ — Scipher Medicine, a leader in precision medicine for autoimmune diseases, today...
FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 — Scipher Medicine and Senelix today announced a strategic collaboration to incorporate Scipher’s AI network platform to...
BURLINGTON, Mass.–(BUSINESS WIRE)–Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel...